Access AFP (on DxI 9000 Analyzer)
BECKMAN COULTER, INC. · Decision date Nov 3, 2025
What did the FDA approve?
FDA records P980041/S051 as a supplement to PMA P980041, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 3, 2025.
FDA approval order statement
migration of the Access AFP to the DxI 9000 Access Immunoassay Analyzer.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Immunology
- Decision date
- Nov 3, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P980041/S051
- Regulatory pathway
- PMA supplement
- Applicant
- BECKMAN COULTER, INC.
- Product code
- LOK
- Decision code
- APPR
- Decision date
- Nov 3, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.
- Applicant
- BECKMAN COULTER, INC.
- Product code
- LOK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P980041/S051 received
Application receipt date recorded by FDA.
P980041/S051 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P980041. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LOK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems AFPP010007/S028 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
IMMULITE Systems AFPP010007/S027 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE 2000 AFPP010007/S026 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Jul 27, 2026 | FDA |
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S032 | ABBOTT LABORATORIES | PMA supplement | May 11, 2026 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA supplement | May 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
BECKMAN COULTER, INC.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 250 S. Kraemer Blvd. M/S, W-110, Brea, CA, 92822
Sources and methodology
- Original FDA record: P980041/S051
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


